Models and mechanisms of vascular dementia

Experimental Neurology

Volumn 272, Issue , 2015, Pages 97-108

  Venkat, Poornima ^a,b   Chopp, Michael ^a,b   Chen, Jieli ^a,c  

^a HENRY FORD HOSPITAL   (United States)

^b OAKLAND UNIVERSITY   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cognition; High fat diet; Multiple infarct dementia; Treatment; Vascular dementia

Indexed keywords

BIOLOGICAL MARKER; DONEPEZIL; MEMANTINE; RESVERATROL; SIMVASTATIN;

AGE; ANIMAL BEHAVIOR; CELL THERAPY; CHOLESTEROL STONE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COMMON CAROTID ARTERY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPERTENSION; LIPID DIET; METABOLIC SYNDROME X; MOLECULAR MECHANICS; MULTIINFARCT DEMENTIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RODENT MODEL; TASK PERFORMANCE; THROMBOEMBOLISM; VERTEBRAL ARTERY; ALZHEIMER DISEASE; ANIMAL; COGNITION DISORDERS; COMPLICATION; DEMENTIA, VASCULAR; DISEASE COURSE; METABOLIC DISORDER; RISK FACTOR;

ALZHEIMER DISEASE; ANIMALS; COGNITION DISORDERS; DEMENTIA, VASCULAR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; HYPERTENSION; METABOLIC DISEASES; RISK FACTORS;

EID: 84945443706     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.05.006     Document Type: Review

References (165)

1. Plassman B.L., et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007, 29(1-2):125-132.
2. Xu W., et al. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 2009, 58(1):71-77.
3. Peila R., Rodriguez B.L., Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002, 51(4):1256-1262.
4. Leibson C.L., et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am. J. Epidemiol. 1997, 145(4):301-308.
5. Kimm H., et al. Mid-life and late-life vascular risk factors and dementia in Korean men and women. Arch. Gerontol. Geriatr. 2011, 52(3):6.
6. Ott A., et al. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999, 53(9):1937-1942.
7. Xu W., et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 2010, 59(11):2928-2935.
8. Bruce D.G., et al. Predictors of cognitive impairment and dementia in older people with diabetes. Diabetologia 2008, 51(2):241-248.
9. Sonnen J.A., et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch. Neurol. 2009, 66(3):315-322.
10. van Harten B., et al. Brain imaging in patients with diabetes: a systematic review. Diabetes Care 2006, 29(11):2539-2548.
11. Idris I., Thomson G.A., Sharma J.C. Diabetes mellitus and stroke. Int. J. Clin. Pract. 2006, 60(1):48-56.
12. Barrett-Connor E., Khaw K.-T. Diabetes mellitus: an independent risk factor for stroke?. Am. J. Epidemiol. 1988, 128(1):116-123.
13. You R., et al. Risk factors for lacunar infarction syndromes. Neurology 1995, 45(8):1483-1487.
14. Weir C.J., et al. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study. BMJ 1997, 314(7090):1303.
15. Megherbi S.E., et al. Association between diabetes and stroke subtype on survival and functional outcome 3months after stroke: data from the European BIOMED Stroke Project. Stroke 2003, 34(3):688-694.
16. Anderson G.H. Effect of age on hypertension: analysis of over 4,800 referred hypertensive patients. Saudi J. Kidney Dis. Transpl. 1999, 10(3):286-297.
17. Kennelly S.P., Lawlor B.A., Kenny R.A. Blood pressure and dementia - a comprehensive review. Ther. Adv. Neurol. Disord. 2009, 2(4):241-260.
18. Yamada M., et al. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J. Am. Geriatr. Soc. 2003, 51(3):410-414.
19. Ronnemaa E., et al. Vascular risk factors and dementia: 40-year follow-up of a population-based cohort. Dement. Geriatr. Cogn. Disord. 2011, 31(6):460-466.
20. Launer L.J., et al. Midlife blood pressure and dementia: the Honolulu-Asia Aging Study. Neurobiol. Aging 2000, 21(1):49-55.
21. Korf E.S., et al. Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension 2004, 44(1):29-34.
22. Verhaaren B.F., et al. High blood pressure and cerebral white matter lesion progression in the general population. Hypertension 2013, 61(6):1354-1359.
23. Tzourio C., et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med. 2003, 163(9):1069-1075.
24. Forette F., et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 2002, 162(18):2046-2052.
25. Farmer M.E., et al. Blood pressure and cognitive performance. The Framingham Study. Am. J. Epidemiol. 1987, 126(6):1103-1114.
26. Guo Z., et al. Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ 1996, 312(7034):805-808.
27. Zhu L., et al. Blood pressure reduction, cardiovascular diseases, and cognitive decline in the mini-mental state examination in a community population of normal very old people: a three-year follow-up. J. Clin. Epidemiol. 1998, 51(5):385-391.
28. Qiu C., et al. Decline in blood pressure over time and risk of dementia: a longitudinal study from the Kungsholmen project. Stroke 2004, 35(8):1810-1815.
29. Grundy S.M., et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart. Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004 Feb 3, 109(4):551-556.
30. Frisardi V. Impact of metabolic syndrome on cognitive decline in older age: protective or harmful, where is the pitfall?. J. Alzheimers Dis. 2014, 4:4.
31. Siervo M., et al. Metabolic syndrome and longitudinal changes in cognitive function: a systematic review and meta-analysis. J. Alzheimers Dis. 2014, 27:27.
32. Rouch I., et al. Metabolic syndrome is associated with poor memory and executive performance in elderly community residents: the PROOF study. Am. J. Geriatr. Psychiatry 2014, 25(14):32-33.
33. Liu C.L., et al. Late-life metabolic syndrome prevents cognitive decline among older men aged 75years and over: one-year prospective cohort study. J. Nutr. Health Aging 2013, 17(6):523-526.
34. Raffaitin C., et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 2009, 32(1):169-174.
35. Birdsill A.C., et al. Low cerebral blood flow is associated with lower memory function in metabolic syndrome. Obesity 2013, 21(7):1313-1320.
36. Solfrizzi V., et al. Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on Aging. Neurobiol. Aging 2011, 32(11):1932-1941.
37. Solfrizzi V., et al. Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. J. Neurol. Neurosurg. Psychiatry 2010, 81(4):433-440.
38. Yaffe K., et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004, 292(18):2237-2242.
39. Lee A.Y. Vascular dementia. Chonnam. Med. J. 2011, 47(2):66-71.
40. Wetterling T., Kanitz R.D., Borgis K.J. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke 1996, 27(1):30-36.
41. Spinetta M.J., et al. Alcohol-induced retrograde memory impairment in rats: prevention by caffeine. Psychopharmacology 2008, 201(3):361-371.
42. Stuart S.A., et al. Chronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memory. PLoS One 2013, 8(9):e75467.
43. Brown R., Corey S., Moore A. Differences in measures of exploration and fear in MHC-congenic C57BL/6J and B6-H-2K mice. Behav. Genet. 1999, 29(4):263-271.
44. Ohno M., et al. Differential effects of alphaCaMKII mutation on hippocampal learning and changes in intrinsic neuronal excitability. Eur. J. Neurosci. 2006, 23(8):2235-2240.
45. Ishiyama T., et al. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur. J. Pharmacol. 2007, 572(2-3):160-170.
46. Weiss C., Shroff A., Disterhoft J.F. Spatial learning and memory in aging C57BL/6 mice. Neurosci. Res. Commun. 1998, 23(2):77-92.
47. Nanri M., Watanabe H. Availability of 2VO rats as a model for chronic cerebrovascular disease. Nihon Yakurigaku Zasshi 1999, 113(2):85-95.
48. Soria G., et al. The ins and outs of the BCCAo model for chronic hypoperfusion: a multimodal and longitudinal MRI approach. PLoS One 2013, 8(9):e74631.
49. Wakita H., et al. Glial activation and white matter changes in the rat brain induced by chronic cerebral hypoperfusion: an immunohistochemical study. Acta Neuropathol. 1994, 87(5):484-492.
50. Ueno M., et al. Blood-brain barrier disruption in white matter lesions in a rat model of chronic cerebral hypoperfusion. J. Cereb. Blood Flow Metab. 2002, 22(1):97-104.
51. Sarti C., et al. Persistent impairment of gait performances and working memory after bilateral common carotid artery occlusion in the adult Wistar rat. Behav. Brain Res. 2002, 136(1):13-20.
52. Lee S., et al. Depressive-like behaviors in a rat model of chronic cerebral hypoperfusion. Transl. Stroke Res. 2014, 1-8.
53. Zhang Z.H., et al. Comparison of cognitive performance between two rat models of vascular dementia. Int. J. Neurosci. 2014, 124(11):818-823.
54. de Bortoli V.C., et al. Inhibitory avoidance memory retention in the elevated T-maze is impaired after perivascular manipulation of the common carotid arteries. Life Sci. 2005, 76(18):2103-2114.
55. Farkas E., Luiten P.G., Bari F. Permanent, bilateral common carotid artery occlusion in the rat: a model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Res. Rev. 2007, 54(1):162-180.
56. Walker E.J., Rosenberg G.A. Divergent role for MMP-2 in myelin breakdown and oligodendrocyte death following transient global ischemia. J. Neurosci. Res. 2010, 88(4):764-773.
57. Lai M., et al. Forebrain mineralocorticoid receptor overexpression enhances memory, reduces anxiety and attenuates neuronal loss in cerebral ischaemia. Eur. J. Neurosci. 2007, 25(6):1832-1842.
58. Kitamura A., et al. Selective white matter abnormalities in a novel rat model of vascular dementia. Neurobiol. Aging 2012, 33(5):1.
59. Stevens W.D., Fortin T., Pappas B.A. Retinal and optic nerve degeneration after chronic carotid ligation: time course and role of light exposure. Stroke 2002, 33(4):1107-1112.
60. Yamamoto H., et al. Complex neurodegeneration in retina following moderate ischemia induced by bilateral common carotid artery occlusion in Wistar rats. Exp. Eye Res. 2006, 82(5):767-779.
61. Marosi M., et al. Hippocampal (CA1) activities in Wistar rats from different vendors. Fundamental differences in acute ischemia. J. Neurosci. Methods 2006, 156(1-2):231-235.
62. Kunze A., et al. Strain differences in fatigue and depression after experimental stroke. Transl. Stroke Res. 2014, 5(5):604-611.
63. Pulsinelli W.A., Brierley J.B. A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke 1979, 10(3):267-272.
64. Neto C.J., et al. Permanent, 3-stage, 4-vessel occlusion as a model of chronic and progressive brain hypoperfusion in rats: a neurohistological and behavioral analysis. Behav. Brain Res. 2005, 160(2):312-322.
65. Pulsinelli W.A., Buchan A.M. The four-vessel occlusion rat model: method for complete occlusion of vertebral arteries and control of collateral circulation. Stroke 1988, 19(7):913-914.
66. Ferreira E.D., et al. Middle-aged, but not young, rats develop cognitive impairment and cortical neurodegeneration following the four-vessel occlusion/internal carotid artery model of chronic cerebral hypoperfusion. Eur. J. Neurosci. 2011, 34(7):1131-1140.
67. Dias Fiuza Ferreira E., et al. Sildenafil provides sustained neuroprotection in the absence of learning recovery following the 4-vessel occlusion/internal carotid artery model of chronic cerebral hypoperfusion in middle-aged rats. Brain Res. Bull. 2013, 90:58-65.
68. Kim Y.O., et al. Effects of sinapic acid of 4 vessel occlusion model-induced ischemia and cognitive impairments in the rat. Clin. Psychopharmacol. Neurosci. 2011, 9(2):86-90.
69. Cespedes A.E., Arango C.A., Cardona G.P. Injury markers in two models of cerebral ischemia. Biomedica 2013, 33(2):292-305.
70. Yoshizaki K., et al. Chronic cerebral hypoperfusion induced by right unilateral common carotid artery occlusion causes delayed white matter lesions and cognitive impairment in adult mice. Exp. Neurol. 2008, 210(2):585-591.
71. Zhao Y., et al. Chronic cerebral hypoperfusion causes decrease of O-GlcNAcylation, hyperphosphorylation of tau and behavioral deficits in mice. Front. Aging Neurosci. 2014, 6:10.
72. Shibata M., et al. White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke 2004, 35(11):2598-2603.
73. Nishio K., et al. A mouse model characterizing features of vascular dementia with hippocampal atrophy. Stroke 2010, 41(6):1278-1284.
74. Nakaji K., et al. Matrix metalloproteinase-2 plays a critical role in the pathogenesis of white matter lesions after chronic cerebral hypoperfusion in rodents. Stroke 2006, 37(11):2816-2823.
75. Shibata M., et al. Selective impairment of working memory in a mouse model of chronic cerebral hypoperfusion. Stroke 2007, 38(10):2826-2832.
76. Ihara M., Tomimoto H. Lessons from a mouse model characterizing features of vascular cognitive impairment with white matter changes. J. Aging Res. 2011, 2011.
77. Khan M., et al. Remote ischemic postconditioning: harnessing endogenous protection in a murine model of vascular cognitive impairment. Transl. Stroke Res. 2015, 6(1):69-77.
78. Arvanitakis Z., et al. Microinfarct pathology, dementia, and cognitive systems. Stroke 2011, 42(3):722-727.
79. Purandare N., et al. Association of cerebral emboli with accelerated cognitive deterioration in Alzheimer's disease and vascular dementia. Am. J. Psychiatry 2012, 169(3):300-308.
80. Zhang H.A., et al. Evaluation of hippocampal injury and cognitive function induced by embolization in the rat brain. Anat. Rec. 2013, 296(8):1207-1214.
81. Takagi K., Takeo S. The model of stroke induced by microsphere embolism in rats. Nihon Yakurigaku Zasshi 2003, 121(6):440-446.
82. Miyake K., Takeo S., Kaijihara H. Sustained decrease in brain regional blood flow after microsphere embolism in rats. Stroke 1993, 24(3):415-420.
83. Fukatsu T., et al. Effects of nefiracetam on spatial memory function and acetylcholine and GABA metabolism in microsphere-embolized rats. Eur. J. Pharmacol. 2002, 453(1):59-67.
84. Takagi N., et al. Failure in learning task and loss of cortical cholingergic fibers in microsphere-embolized rats. Exp. Brain Res. 1997, 114(2):279-287.
85. Kiyota Y., et al. Cerebral embolization leads to memory impairment of several learning tasks in rats. Pharmacol. Biochem. Behav. 1986, 24(3):687-692.
86. Rapp J.H., et al. Microemboli composed of cholesterol crystals disrupt the blood-brain barrier and reduce cognition. Stroke 2008, 39(8):2354-2361.
87. Wang M., et al. Cognitive deficits and delayed neuronal loss in a mouse model of multiple microinfarcts. J. Neurosci. 2012, 32(50):17948-17960.
88. Rapp J.H., Hollenbeck K., Pan X.M. An experimental model of lacunar infarction: embolization of microthrombi. J. Vasc. Surg. 2008, 48(1):196-200.
89. Shih A.Y., et al. The smallest stroke: occlusion of one penetrating vessel leads to infarction and a cognitive deficit. Nat. Neurosci. 2013, 16(1):55-63.
90. Winocur G., Greenwood C.E. Studies of the effects of high fat diets on cognitive function in a rat model. Neurobiol. Aging 2005, 1:46-49.
91. Kalmijn S., et al. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann. Neurol. 1997, 42(5):776-782.
92. Davidson T.L., et al. Inter-relationships among diet, obesity and hippocampal-dependent cognitive function. Neuroscience 2013, 253:110-122.
93. Engelhart M.J., et al. Diet and risk of dementia: does fat matter?: the Rotterdam Study. Neurology 2002, 59(12):1915-1921.
94. Pistell P.J., et al. Cognitive impairment following high fat diet consumption is associated with brain inflammation. J. Neuroimmunol. 2010, 219(1-2):25-32.
95. Morrison C.D., et al. High fat diet increases hippocampal oxidative stress and cognitive impairment in aged mice: implications for decreased Nrf2 signaling. J. Neurochem. 2010, 114(6):1581-1589.
96. Yamori Y., et al. Pathogenetic similarity of strokes in stroke-prone spontaneously hypertensive rats and humans. Stroke 1976, 7(1):46-53.
97. Yamaguchi M., et al. Memory deficit accompanying cerebral neurodegeneration after stroke in stroke-prone spontaneously hypertensive rats (SHRSP). Acta Neurochir. Suppl. 1994, 60:200-202.
98. Jalal F.Y., et al. Myelin loss associated with neuroinflammation in hypertensive rats. Stroke 2012, 43(4):1115-1122.
99. Fredriksson K., et al. Cerebrovascular lesions in stroke-prone spontaneously hypertensive rats. Acta Neuropathol. 1985, 68(4):284-294.
100. Chiba T., et al. Interleukin-1beta accelerates the onset of stroke in stroke-prone spontaneously hypertensive rats. Mediat. Inflamm. 2012, 2012:701976.
101. Henning E.C., Warach S., Spatz M. Hypertension-induced vascular remodeling contributes to reduced cerebral perfusion and the development of spontaneous stroke in aged SHRSP rats. J. Cereb. Blood Flow Metab. 2010, 30(4):827-836.
102. Schreiber S., et al. Blood brain barrier breakdown as the starting point of cerebral small vessel disease? - new insights from a rat model. Exp. Transl. Stroke Med. 2013, 5(1):4.
103. Li H., et al. Evaluation of the protective potential of brain microvascular endothelial cell autophagy on blood-brain barrier integrity during experimental cerebral ischemia-reperfusion injury. Transl. Stroke Res. 2014, 5(5):618-626.
104. Sabbatini M., et al. The hippocampus in spontaneously hypertensive rats: an animal model of vascular dementia?. Mech. Ageing Dev. 2002, 123(5):547-559.
105. Kaiser D., et al. Spontaneous white matter damage, cognitive decline and neuroinflammation in middle-aged hypertensive rats: an animal model of early-stage cerebral small vessel disease. Acta Neuropathol. Commun. 2014, 2(1):169.
106. King A.J. The use of animal models in diabetes research. Br. J. Pharmacol. 2012, 166(3):877-894.
107. Huber J.D., VanGilder R.L., Houser K.A. Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats. Am. J. Physiol. Heart Circ. Physiol. 2006, 291(6):H2660-H2668.
108. Thomas J., Garg M.L., Smith D.W. Dietary resveratrol supplementation normalizes gene expression in the hippocampus of streptozotocin-induced diabetic C57Bl/6 mice. J. Nutr. Biochem. 2014, 25(3):313-318.
109. Kawamoto E.M., et al. TLR4-dependent metabolic changes are associated with cognitive impairment in an animal model of type 1 diabetes. Biochem. Biophys. Res. Commun. 2014, 443(2):731-737.
110. Alvarez E.O., et al. Cognitive dysfunction and hippocampal changes in experimental type 1 diabetes. Behav. Brain Res. 2009, 198(1):224-230.
111. Won S.J., et al. Recurrent/moderate hypoglycemia induces hippocampal dendritic injury, microglial activation, and cognitive impairment in diabetic rats. J. Neuroinflammation 2012, 9:182.
112. Tsukuda K., et al. Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. Hypertension 2007, 50(6):1099-1105.
113. Serlin Y., Levy J., Shalev H. Vascular pathology and blood-brain barrier disruption in cognitive and psychiatric complications of type 2 diabetes mellitus. Cardiovasc. Psychiatry Neurol. 2011, 2011:609202.
114. Wang J.Q., et al. Brain aging and AD-like pathology in streptozotocin-induced diabetic rats. J. Diabetes Res. 2014, 2014:796840.
115. Li X., Song D., Leng S.X. Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment. Clin. Interv. Aging 2015, 10:549-560.
116. Goldman H., et al. Cerebrovascular permeability and cognition in the aging rat. Neurobiol. Aging 1992, 13(1):57-62.
117. Park L., et al. Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J. Cereb. Blood Flow Metab. 2007, 27(12):1908-1918.
118. Manwani B., et al. Perfusion of ischemic brain in young and aged animals: a laser speckle flowmetry study. Stroke 2014, 45(2):571-578.
119. Lindner M.D., et al. Long-lasting functional disabilities in middle-aged rats with small cerebral infarcts. J. Neurosci. 2003, 23(34):10913-10922.
120. Bruley-Rosset M., et al. Prevention of spontaneous tumors of aged mice by immunopharmacologic manipulation: study of immune antitumor mechanisms. J. Natl. Cancer Inst. 1981, 66(6):1113-1119.
121. Li W.Z., et al. Protective effect of bilobalide on learning and memory impairment in rats with vascular dementia. Mol. Med. Rep. 2013, 8(3):935-941.
122. Ma X., et al. Resveratrol improves cognition and reduces oxidative stress in rats with vascular dementia. Neural. Regen. Res. 2013, 8(22):2050-2059.
123. Zhang X., et al. Effects of acupuncture on declined cerebral blood flow, impaired mitochondrial respiratory function and oxidative stress in multi-infarct dementia rats. Neurochem. Int. 2014, 65:23-29.
124. Huang J.L., et al. Protective effects of Nicotiflorin on reducing memory dysfunction, energy metabolism failure and oxidative stress in multi-infarct dementia model rats. Pharmacol. Biochem. Behav. 2007, 86(4):741-748.
125. Ritz M.F., et al. Gene expression suggests spontaneously hypertensive rats may have altered metabolism and reduced hypoxic tolerance. Curr. Neurovasc. Res. 2012, 9(1):10-19.
126. Liu H., Zhang J. Cerebral hypoperfusion and cognitive impairment: the pathogenic role of vascular oxidative stress. Int. J. Neurosci. 2012, 122(9):494-499.
127. Gill R., Tsung A., Billiar T. Linking oxidative stress to inflammation: toll-like receptors. Free Radic. Biol. Med. 2010, 48(9):1121-1132.
128. Candelario-Jalil E., et al. Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment. Stroke 2011, 42(5):1345-1350.
129. Reuter B., et al. Effect of simvastatin on MMPs and TIMPs in human brain endothelial cells and experimental stroke. Transl. Stroke Res. 2015, 6(2):156-159.
130. Iemolo F., et al. Pathophysiology of vascular dementia. Immun. Ageing 2009, 6:13.
131. Li W., Lai X.S. Changes of interleukin-1beta and TNF-alpha contents in the hippocampus and the interventional effect of electroacupuncture in vascular dementia rats. Zhen Ci Yan Jiu 2007, 32(1):34-37.
132. Chen J., et al. White matter damage and the effect of matrix metalloproteinases in type 2 diabetic mice after stroke. Stroke 2011, 42(2):445-452.
133. Wang J., Zhang H.Y., Tang X.C. Huperzine a improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion. J. Neurosci. Res. 2010, 88(4):807-815.
134. Back S.A., et al. Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J. Neurosci. 2002, 22(2):455-463.
135. Ihara M., et al. Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies. Acta Neuropathol. 2010, 119(5):579-589.
136. Park H.R., et al. A high-fat diet impairs neurogenesis: involvement of lipid peroxidation and brain-derived neurotrophic factor. Neurosci. Lett. 2010, 482(3):235-239.
137. Stranahan A.M., et al. Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 2008, 18(11):1085-1088.
138. Chen J., et al. Neurorestorative therapy for stroke. Front. Hum. Neurosci. 2014, 8:382.
139. Stanimirovic D.B., Friedman A. Pathophysiology of the neurovascular unit: disease cause or consequence?. J. Cereb. Blood Flow Metab. 2012, 32(7):1207-1221.
140. Barker R., et al. Pathophysiology of white matter perfusion in Alzheimer's disease and vascular dementia. Brain 2014, 137(Pt 5):1524-1532.
141. Song J., et al. Association between risk factors for vascular dementia and adiponectin. Biomed. Res. Int. 2014, 2014:261672.
142. Brun A. Pathology and pathophysiology of cerebrovascular dementia: pure subgroups of obstructive and hypoperfusive etiology. Dementia 1994, 5(3-4):145-147.
143. Rohn T.T. Is apolipoprotein E4 an important risk factor for vascular dementia?. Int. J. Clin. Exp. Pathol. 2014, 7(7):3504-3511.
144. Rohn T.T., et al. Apolipoprotein E pathology in vascular dementia. Int. J. Clin. Exp. Pathol. 2014, 7(3):938-947.
145. Can O.D., et al. The effect of simvastatin treatment on behavioral parameters, cognitive performance, and hippocampal morphology in rats fed a standard or a high-fat diet. Behav. Pharmacol. 2012, 23(5-6):582-592.
146. Mok V.C., et al. Effects of statins on the progression of cerebral white matter lesion: post hoc analysis of the ROCAS (Regression of Cerebral Artery Stenosis) study. J. Neurol. 2009, 256(5):750-757.
147. Lai T.W., Zhang S., Wang Y.T. Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog. Neurobiol. 2014, 115:157-188.
148. Orgogozo J.M., et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002, 33(7):1834-1839.
149. Lipton S.A. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 2004, 1(1):101-110.
150. Wilkinson D., et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003, 61(4):479-486.
151. Wilkinson D., et al. The long-term efficacy and tolerability of donepezil in patients with vascular dementia. Int. J. Geriatr. Psychiatry 2010, 25(3):305-313.
152. Dunn N.R., Pearce G.L., Shakir S.A. Adverse effects associated with the use of donepezil in general practice in England. J. Psychopharmacol. 2000, 14(4):406-408.
153. Liu J., et al. Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials. Prog. Neurobiol. 2014, 115:138-156.
154. Liu X., et al. Cell based therapies for ischemic stroke: from basic science to bedside. Prog. Neurobiol. 2014, 115:92-115.
155. Yan T., et al. HUCBCs increase angiopoietin 1 and induce neurorestorative effects after stroke in T1DM rats. CNS Neurosci. Ther. 2014, 20(10):935-944.
156. Chen J., et al. Neurorestorative therapy for stroke. Front. Hum. Neurosci. 2014, 8(382).
157. Cui X., et al. Therapeutic benefit of treatment of stroke with simvastatin and human umbilical cord blood cells: neurogenesis, synaptic plasticity, and axon growth. Cell Transplant. 2012, 21(5):845-856.
158. Darlington D., et al. Multiple low-dose infusions of human umbilical cord blood cells improve cognitive impairments and reduce amyloid-beta-associated neuropathology in Alzheimer mice. Stem Cells Dev. 2013, 22(3):412-421.
159. de Paula S., et al. The dose-response effect of acute intravenous transplantation of human umbilical cord blood cells on brain damage and spatial memory deficits in neonatal hypoxia-ischemia. Neuroscience 2012, 210:431-441.
160. Sunwoo M.K., et al. Mesenchymal stem cells can modulate longitudinal changes in cortical thickness and its related cognitive decline in patients with multiple system atrophy. Front. Aging Neurosci. 2014, 6(118).
161. Li X.M., et al. Resveratrol pretreatment attenuates the isoflurane-induced cognitive impairment through its anti-inflammation and -apoptosis actions in aged mice. J. Mol. Neurosci. 2014, 52(2):286-293.
162. Belarbi K., et al. TNF-alpha protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. J. Neuroinflammation 2012, 9(23):1742-2094.
163. Tweedie D., Sambamurti K., Greig N.H. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr. Alzheimer Res. 2007, 4(4):378-385.
164. Ruan L., et al. Neurogenesis in neurological and psychiatric diseases and brain injury: from bench to bedside. Prog. Neurobiol. 2014, 115:116-137.
165. An C., et al. Molecular dialogs between the ischemic brain and the peripheral immune system: dualistic roles in injury and repair. Prog. Neurobiol. 2014, 115:6-24.